aspartate

N-Palmitoyl-L-aspartate (L-N-Palmitoylaspartic acid) is a surfactant used in detergents and is commonly used in the skin care industry.

L-Ornithine L-aspartate (Ornithine Aspartate) lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.

Agonist at NMDA receptors and EAAT substrate

Lysine aspartate is a bioactive chemical.

Tenofovir disoproxil aspartate, a nucleotide reverse transcriptase inhibitor, is used potentially for the treatment of HBV infection.

Mab Aspartate Decarboxylase-IN-1 is a potent inhibitor of aspartate decarboxylase (PanD) (IC50 = 56.3 μM) with antibacterial activity [1].

Erythromycin aspartate is a enzyme.

Pasireotide L-aspartate salt is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9 respectively).

β-Methyl L-aspartate hydrochloride (L-Aspartic acid β-methyl ester hydrochloride) is an aspartic acid derivative commonly used to synthesize various compounds and is related to body immunity and metabolism.

Lomefloxacin (SC47111A) aspartate is a broad-spectrum quinolone antibacterial agent that can be used in the study of respiratory tract infections, gastrointestinal infections, genitourinary infections, and ear, nose, and throat infections.

Aspartate aminotransferase (AST) is a transaminase enzyme, is often used in biochemical studies. Aspartate aminotransferase catalyzes aspartate and alpha-ketoglutarate converts to oxaloacetate and glutamate. Aspartate aminotransferase can be found in cerebrospinal fluid, exudates, and transudates [1] .

Methotrexate-gamma-aspartate has growth inhibitory effects. It is used in antibody-targeted liposomes.

L-aspartic acid potasium salt（VX-548） is an amino acid widely found in plants and animals.L-aspartic acid potasium salt drives the production of nitrogen oxides, which promotes phagocytosis and contributes to fish survival.L-aspartic acid potasium salt may stimulate antibiotics. The stimulatory effect may be related to precursors involved in aspartic acid-4-semialdehyde biosynthesis.

L-Aspartic aicd sodium (Sodium L-aspartate) is an amino acid, a precursor active molecule for colon-specific active molecule delivery, that promotes Na+ efflux from rat forebrain membrane vesicles.

Sparfosic Acid (Acide sparfosique) is an aspartate carbamoyltransferase inhibitor with antitumor activity and can be used to study advanced renal cell carcinoma.

Aspartic acid calcium (Calcium L-aspartate) (Calcium L-aspartate) is a chelate where calcium is attached to an amino acid naming L-Aspartic acid, which is an amino acid and serves as a building block for proteins in the body.

Amlodipine aspartic acid is a calcium channel blocker compound that exhibits antihypertensive and antianginal properties. It is important to note that Amlodipine aspartic acid impurity is an impurity specific to this compound.

LY339434 HCl is a low affinity GluR5 erythrocyte receptor agonist.LY339434 HCl causes rapid neuronal death primarily by affecting N-methyl-D-aspartate (NMDA) receptors.

L-Cysteine S-sulfate (S-Sulfo-L-cysteine) is an effective N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate is the substrate for cystine lyase [1].

Orphenadrine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that inhibits clonal HERG channels in a concentration-dependent manner, producing an IC of 0.85 μM in HEK cells.Orphenadrine is an antagonist of central and peripheral muscarinic receptors. Attenuation is blocked by mutations in pore residues Y652 or F656. Orphenadrine has antispasmodic, analgesic, and anticholinergic activity and protects against glutamatergic neurotoxicity in vitro and in vivo.Orphenadrine has inhibitory effects on sodium channels and can be used in the treatment of Parkinson's disease.

MK-801 (Dizocilpine (MK-801)) is a potent N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 30.5 nM.

Trans-ACBD (Trans-1-aminocyclobutane-1,3-dicarboxylic acid) is an effective and specific N-methyl-D-aspartate receptor agonist.

NP10679 is an orally available, selective, brain-penetrating, potent, and pH-sensitive N-methyl-D-aspartate (NMDA) receptor inhibitor of the GluN2B subunit.NP10679 inhibits histamine H1, hERG channels, and CYP enzymes, and may be useful in the study of epilepsy and ischemic stroke.

Gacyclidine (OTO311) is a small molecule N-methyl-D-aspartate (NMDA) receptor antagonist. Local injection of Gacyclidine in the cochlea inhibits salicylate-induced tinnitus and can be used to treat brain injury, spinal cord injury and tinnitus.

Metapramine (19560 RP) is a novel psychostimulant, an N-methyl-D-aspartate receptor (NMDA) antagonist with antidepressant and anti-injury perception activity that promotes increased levels of acetylcholine in the striatum.

Rapastinel acetate is a modulator of N-methyl-D-aspartate (NMDA) receptor and a partial agonist of glycine site long-lasting antidepressant effects.

1-Adamantylaspartate can be used as a protecting group for protein synthesis.

Pasireotide diaspartate (SOM230), a long-acting cyclohexapeptide and somatostatin analog, enhances agonist activity across somatostatin receptor subtypes (sst1/2/3/4/5, with pK i values of 8.2, 9.0, 9.1, <7.0, and 9.9, respectively). This compound demonstrates antisecretory, antiproliferative, and proapoptotic activities [1] [2].

Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Lithium citrate decreases elevated intracerebral N-acetyl aspartate levels in Canavan disease [1].

Nitisinone-13C6is intended for use as an internal standard for the quantification of nitisinone by GC- or LC-MS. Nitisinone is an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD), which converts 4-hydroxyphenylpyruvate (HPPA) to homogentisate in the tyrosine catabolic pathway.1Nitisinone increases urinary levels of HPPA and 4-hydroxyphenyllactate (HPLA) in rats when administered at a dose of 10 mg/kg. Nitisinone (3 mg/kg) prevents the neonatal lethality of fumarylacetoacetate hydrolase (FAH) deficiency in mice when administered to pregnant dams.2It exhibits hepatoprotective effects inFAH-/-mice, such as prevention of increases in plasma levels of aspartate serine aminotransferase (AST) and conjugated bilirubin, when administration is continued following birth at a dose of 1 mg/kg. Nitisinone (100 μg) decreases urinary excretion of homogentisate and increases urinary excretion of HPPA, HPLA, and 4-hydroxyphenylacetate in a mouse model of alkaptonuria induced by ethylnitrosourea.3Formulations containing nitisinone have been used in the treatment of hereditary tyrosinemia type 1 (HT-1). 1.Ellis, M.K., Whitfield, A.C., Gowans, L.A., et al.Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dioneToxicol. Appl. Pharmacol.133(1)12-19(1995) 2.Grompe, M., Lindstedt, S., al-Dhalimy, M., et al.Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type INat. Genet.10(4)453-460(1995) 3.Suzuki, Y., Oda, K., Yoshikawa, Y., et al.A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuriaJ. Hum. Genet.44(2)79-84(1999)

GluN1 (359-378) is an antibody targeting the N-methyl-D-aspartate receptor (NMDAR) capable of crossing the blood-brain barrier and is utilized in researching therapies for anti-NMDAR encephalitis that focus on the immune system [1].

L-689560 is widely used as a radiolabeled ligand in binding studies and used to study the roles of NMDA receptors in normal neurological processes as well as in diseases. At the GluN1 glycine binding site, L-689560 is an effective N-methyl-D-aspartate (NM

L-Cysteic acid monohydrate (3-Sulfo-L-alanine Monohydrate) is an oxidation product of L-cysteine that may be used as a competitive inhibitor of the bacterial aspartate: alanine antiporter (AspT) exchange of aspartate and in other aspartate biological systems. L-Cysteic acid monohydrate is used in monomeric surfactant development. L-Cysteic acid monohydrate may be used in studies of excitatory amino acids in the brain, such as those that bind to cysteine sulfinic acid receptors. It is a useful agonist at several rat metabotropic glutamate receptors (mGluRs).

PACAP (1-38) free acid, an endogenous neuropeptide, potently modulates gastrointestinal and neuroendocrine functions. It enhances antral motility, increases somatostatin secretion, and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide, and substance P, while concurrently inhibiting gastrin secretion. Additionally, it augments N-methyl-D-aspartate receptor function and upregulates brain-derived neurotrophic factor expression via RACK1 [1] [2].

PACAP (1-38) free acid TFA, an endogenous neuropeptide, effectively enhances antral motility and somatostatin secretion, while concurrently suppressing gastrin secretion and promoting the release of vasoactive intestinal polypeptide, gastrin releasing peptide, and substance P. Additionally, it amplifies N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1 [1] [2].

Alamandine can be formed from angiotensin A by action of ACE-2 or directly from angiotensin-(1-7) by decarboxylation of its aspartate residue. The angiotensin A analog produces effects resembling those of Ang II (1-7). However, it acts independently of the two known vasodilators receptors of the RAS (Mas and angiotensin II type 2). To produce its effects, alamandine binds to the Mas-related receptor, MrgD. A novel orally active formulation of alamandine produced a long-term antihypertensive effect in spontaneously hypertensive rats and cardioprotective effects. These novel findings will be helpful for developing a new understanding of the RAS, a key regulator of blood pressure and fluid balance. The heptapeptide could serve as a model peptide, e.g. in the development and evaluation of analytical methods.

GluN1 (356-385) is an antigenic peptide implicated in N-methyl-D-aspartate receptor (NMDAR) encephalitis and has been shown to decrease the density of NMDAR surface clusters in hippocampal neurons. It serves as a tool to investigate the pathogenesis of anti-NMDAR encephalitis [1].

Dihydroquinoline-pyrazoline DQP-997-74 (compound 2i) is a selective N-methyl-d-aspartate receptor (NMDAR) inhibitor that preferentially targets GluN2C/D subunits, with IC50 values of 0.069 μM and 0.035 μM, respectively, and possesses blood-brain barrier permeability. It enhances its inhibitory potency in a time-dependent manner when combined with the agonist glutamate, reducing epileptogenic events in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 is potentially applicable for the study of NMDAR-related neurological diseases [1].

NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.

Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist,is an antiparkinsonian agent.

6-Chloropurine riboside-5'-triphosphate serves as both an inhibitor and an activator in biochemical processes. It inhibits the RNA triphosphatase mRNA-capping enzyme subunit β (Cet1; IC50 = 2 µM for the GTPase activity of the S. cerevisiae enzyme), proving its efficacy against the enzyme responsible for the capping of mRNA molecules. Additionally, it acts as a phosphorylated derivative of 6-chloropurine riboside. This compound also activates the E. coli enzyme aspartate carbamoyltransferase (EC50 = 0.76 mM), demonstrating its versatility in modulating enzyme activities. It is instrumental in the synthesis of cytokinins with anticancer properties and a photoclickable form of ATP, highlighting its applications in biochemical synthesis and potential therapeutic uses.

DPQ is a potent inhibitor of PARP-1 that can be used in neuroprotection research. DPQ reduce the PARP activation induced by N-methyl-d-aspartate (NMDA), restoring ATP to near control levels as well as significantly attenuating neuronal injury in the severe NMDA exposure model [1].

UBP141 is a antagonist of N-methyl-D-aspartate (NMDA) receptor.

ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1/GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg/kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob/obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. 1.Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019) 2.Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)

Cis-ACBD (cis-1-aminocyclobutane-1,3-dicarboxylic acid) is a potent and selective N-methyl-D-aspartate receptor agonist.

Spermidine trihydrochloride (4-Azaoctamethylenediamine trihydrochloride), a natural polyamine, is a novel autophagy inducer and negatively modulates N-methyl-d-aspartate (NMDA).

GOT1 inhibitor-1 (GOT1 inhibitor 2c) is a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC50 of 8.2 uM.

Sepimostat exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a Ki value of 27.7 μM.

EP2 receptor antagonist-2 (CID891729) is a compound that not only serves as an antagonist to the EP2 receptor, blocking its activation by PGE2, but also reduces lactate dehydrogenase (LDH) release triggered by N-methyl-D-aspartate (NMDA).